The Karmanos Cancer Institute requests funds for five Staff Investigators. These five individuals link investigators from different Programs to focus on specific translational areas of research and education and mentoring. The mentorship role of senior investigators is of particular importance in aiding the growth of young scientists. Four of these Staff Investigators provide invaluable mentorship for selected Research Teams. Dr. Shirish Gadgeel (Developmental Therapeutics) is Co-Leader of the Lung Cancer Research Team. Dr. Elisabeth Heath (Developmental Therapeutics) is Leader of the Prostate Cancer Research Team. Dr. Lawrence Lum (Breast Cancer Biology joint with Developmental Therapeutics) is Co-Leader of the Tumor Immunology Research Team. Dr. Larry Matherly (Developmental Therapeutics) is Co-Leader of the Leukemia/Lymphoma Research Team and also leads our Cancer Biology Graduate Program. These four Research Team leaders coordinate research efforts and organize meetings. They encourage inter- and intra-programmatic collaborations with the goal of identifying opportunities for program projects and imminent translation to patient care. They partner with Program Leaders and Research Administration to learn of opportunities for seed funding and pilot projects and integrate these opportunities into the activities and priorities of their respective Research Teams. Infrastructure support, such as IT requirements and meeting preparation, are coordinated by these team leaders. Dr. Avraham Raz (Proteases and Cancer) is proposed as a Staff Investigator in light of his extensive experience and exceptional success in mentoring and advising young and established scientists. In particular, he fosters, advises, mentors, and directs junior scientists toward obtaining independent and collaborative funding. Funding for each of these Staff Investigators is requested at 10% effort.
; Five scientists have been selected to serve as Staff Investigators. Four of these Leaders are chosen to support their activities on their respective Research Teams. The fifth scientist is proposed to support his mentoring and advising activities on behalf of junior scientists.
|Munkanatta Godage, Dhanushka N P; VanHecke, Garrett C; Samarasinghe, Kusal T G et al. (2018) SMYD2 glutathionylation contributes to degradation of sarcomeric proteins. Nat Commun 9:4341|
|Han, Jing; Li, Yue; Liu, Xiuli et al. (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS One 13:e0193031|
|Rathinam, Rajamani; Rosati, Rita; Jamesdaniel, Samson (2018) CRISPR/Cas9-mediated knockout of Lim-domain only four retards organ of Corti cell growth. J Cell Biochem 119:3545-3553|
|Kim, Seongho; Wong, Weng Kee (2018) Discussion on Optimal treatment allocations in space and time for on-line control of an emerging infectious disease. J R Stat Soc Ser C Appl Stat 67:778-779|
|Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315|
|McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K et al. (2018) Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep 8:9043|
|An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319|
|Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238|
|Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298|
|Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806|
Showing the most recent 10 out of 826 publications